文献速递精神分裂症与精神病性障碍

难治性精神分裂症的遗传风险与健康个体多巴胺合成能力及D2/3受体可用性的相应变化

Genetic risk for treatment resistant schizophrenia and corresponding variation in dopamine synthesis capacity and D2/3 receptor availability in healthy individuals.
PubMed 文献 · Mol Psychiatry · 2024-12-27

该研究在无神经精神疾病的健康个体中,采用[18F]-FDOPA PET发现纹状体突触前多巴胺合成能力与一般精神分裂症累积遗传风险呈正向关联,而与难治性精神分裂症特异性多基因风险呈反向关联;采用[18F]-fallypride PET未发现纹状体D2/3受体可用性与遗传风险的关联,但发现丘脑与难治性精神分裂症多基因风险相关。

要点

  • 健康个体纹状体多巴胺合成能力与一般精神分裂症累积遗传风险呈正向关联。
  • 纹状体多巴胺合成能力与难治性精神分裂症特异性多基因风险呈反向关联。
  • 丘脑D2/3受体可用性与难治性精神分裂症多基因风险相关,纹状体未见关联。

核心结论

  • 结果与既往患者PET研究一致,就多巴胺系统而言,难治性精神分裂症独特遗传易感性涉及根本不同的分子机制。

研究设计与样本

  • 研究纳入无神经精神疾病的健康个体队列,使用[18F]-FDOPA PET评估纹状体突触前多巴胺合成能力。
  • 在重叠队列中使用[18F]-fallypride PET评估D2/3多巴胺受体可用性。

主要发现

  • 纹状体突触前多巴胺合成能力与一般精神分裂症累积遗传风险负担呈预期正向关联。
  • 纹状体突触前多巴胺合成能力与难治性精神分裂症特异性多基因风险呈反向关联。
  • 重叠队列中[18F]-fallypride PET未发现纹状体D2/3受体可用性受遗传风险影响。
  • 丘脑D2/3受体可用性与难治性精神分裂症多基因风险存在关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dysfunction of dopamine systems has long been considered a hallmark of schizophrenia, and nearly all current first-line medication treatments block dopamine D2 receptors. However, approximately a quarter of patients will not adequately respond to these agents and are considered treatment-resistant. Whereas abnormally high striatal presynaptic dopamine synthesis capacity has been observed in people with schizophrenia, studies of treatment-resistant patients have not shown this pattern and have even found the opposite - i.e., reductions in striatal presynaptic dopamine synthesis capacity. Whether such reductions in fact represent clinical epiphenomena such as medication or other treatment effects or whether they rather represent neurobiological differences related to etiology has been unclear. To understand the dopaminergic implications of genetic liability for treatment-resistant schizophrenia without the confound of clinical epiphenomena, we studied a cohort of healthy individuals without neuropsychiatric illness using [18F]-FDOPA positron emission tomography (PET) and found that striatal presynaptic dopamine synthesis capacity showed an expected direct association with cumulative genetic risk burden for general schizophrenia but an inverse association with specific polygenic risk for treatment-resistant schizophrenia. Subsequent evaluation of D2/3 dopamine receptor availability in an overlapping cohort using [18F]-fallypride PET did not identify any effects of genetic risk in the striatum but found an association with treatment-resistant schizophrenia polygenic risk in the thalamus. Overall, these results align with prior PET studies in patients and implicate, at least with respect to the dopamine system, fundamentally distinct molecular mechanisms in the unique genetic liability for treatment-resistant schizophrenia.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Eisenberg DP, Blackman RK, Tietcheu MG, et al. Genetic risk for treatment resistant schizophrenia and corresponding variation in dopamine synthesis capacity and D2/3 receptor availability in healthy individuals. Mol Psychiatry. 2024. PMID: 39730881. doi:10.1038/s41380-024-02873-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。